Investing in Eiger BioPharmaceuticals, Inc. (EIGR)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)0.37-84
Intrinsic value (DCF)0.37-84
Graham-Dodd Method0.00-100
Graham Formula31.851285

Company description

Eiger BioPharmaceuticals, Inc. (EIGR) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for rare and ultra-rare diseases. The company's robust pipeline includes therapies for a wide range of diseases such as Hepatitis Delta Virus (HDV) infection, pulmonary arterial hypertension (PAH), and lymphedema. Eiger's lead product candidate, Lonafarnib, has been granted Orphan Drug designation by the FDA and has shown promising results in clinical trials for treating HDV infection, a serious and potentially fatal liver disease. The company is also developing other targeted therapies and has multiple partnerships and collaborations to support its research and development efforts. With a strong management team and a dedicated focus on developing treatments for unmet medical needs, Eiger is well-positioned to continue growing and providing meaningful solutions for patients and their families worldwide.